^
Association details:
| Biomarker: | SLFN11 expression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Excerpt:
We confirmed that SLFN11 transcript and protein expression correlate, by linear regression (p = 0.01; Supplemental Fig 2C). As expected, we established that SLFN11 expression is a determinant of talazoparib sensitivity where a correlative trend by linear regression between SLFN11 protein expression and talazoparib sensitivity was observed, even in this small sample (p = 0.06; Fig 2B).
DOI:
10.1158/1078-0432.CCR-16-1040
